<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404790</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-APT-201803</org_study_id>
    <nct_id>NCT04404790</nct_id>
  </id_info>
  <brief_title>Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers</brief_title>
  <official_title>Phase I Clinical Trial of the Tolerance and Pharmacokinetics of Anfibatide in Health Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, dose-escalation, and multidose study, aiming to investigate the
      tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects. The study is
      divided into 2 intravenous single groups and 3 continuous administration groups. The dose of
      Anfibatate from 5 IU/60kg to 7 IU/60kg in intravenous single groups. The dose of Anfibatate
      from 0.002 IU/kg/h, 0.004 IU/kg/h to 0.008 IU/kg/h in continuous administration groups.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Optimization of protocol
  </why_stopped>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Bleeding events are judged according to Bleeding Academic Research Consortium Definition for Bleeding criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Peak time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Area under curve 0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-∞)</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Area under curve 0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Inhibition rate of platelet aggregation is measured by chrono-log700.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corrected QT interval</measure>
    <time_frame>7 days after drug administration</time_frame>
    <description>Corrected QT interval is measured by 12-lead ECG.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Antiplatelet Drug</condition>
  <arm_group>
    <arm_group_label>Anfibatide 5 IU/60kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 5 IU/60kg+0.002 IU/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 5 IU/60kg+0.004 IU/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 5 IU/60kg+0.008 IU/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 7 IU/60kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 7 IU/60kg+0.002 IU/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 7 IU/60kg+0.004 IU/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfibatide 7 IU/60kg+0.008 IU/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 5 IU/60kg</intervention_name>
    <description>5 IU/60kg IV administration of Anfibatide with 5 minutes</description>
    <arm_group_label>Anfibatide 5 IU/60kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 5 IU/60kg +0.002 IU/kg/h</intervention_name>
    <description>5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours</description>
    <arm_group_label>Anfibatide 5 IU/60kg+0.002 IU/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 5 IU/60kg +0.004 IU/kg/h</intervention_name>
    <description>5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours</description>
    <arm_group_label>Anfibatide 5 IU/60kg+0.004 IU/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 5 IU/60kg +0.008 IU/kg/h</intervention_name>
    <description>5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours</description>
    <arm_group_label>Anfibatide 5 IU/60kg+0.008 IU/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 7 IU/60kg</intervention_name>
    <description>7 IU/60kg IV administration of Anfibatide with 5 minutes</description>
    <arm_group_label>Anfibatide 7 IU/60kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 7 IU/60kg +0.002 IU/kg/h</intervention_name>
    <description>7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours</description>
    <arm_group_label>Anfibatide 7 IU/60kg+0.002 IU/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 7 IU/60kg +0.004 IU/kg/h</intervention_name>
    <description>7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours</description>
    <arm_group_label>Anfibatide 7 IU/60kg+0.004 IU/kg/h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide 7 IU/60kg +0.008 IU/kg/h</intervention_name>
    <description>7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours</description>
    <arm_group_label>Anfibatide 7 IU/60kg+0.008 IU/kg/h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female healthy subjects between the ages of 18 to 40 years（including）.

          2. The body mass index（BMI）， in the range of 19 ~ 24 (including).

          3. Medical history without heart, liver, kidney, digestive tract, nervous system,
             metabolic, ulcer, obvious bleeding, and history of drug allergy or postural
             hypotension.

          4. According to the medical history, physical examination, vital signs, chest radiograph,
             12-lead ECG, coagulation routine, stool routine and occult blood test, as well as the
             laboratory results of blood and urine, the subjects are healthy.

          5. The subjects do not take any medicine in the past two weeks.

          6. Willingness to participate the study and sign the written Informed Consent Form.

          7. Non-lactating women willingness to use adequate contraceptive measures (including
             abstinence, intrauterine device, diaphragm and spermicide) during the study (screening
             period to 1 week after administration). Men are willing to use approved methods of
             contraception (including condoms and spermicides or oral, implanted or injectable
             contraceptives by their partners, intrauterine device, diaphragms and spermicides).
             Subjects do not plan to donate sperm or eggs within two weeks after drug
             administration.

        Exclusion Criteria:

          1. Abnormal with the safety evaluation is considered to be clinical significance in
             screening period as judged by the researcher.

          2. Subjects with history of hepatitis B virus, hepatitis C virus, human immunodeficiency
             virus and syphilis virus infection;

          3. Excessive smoking (＞5 cigarettes/day) or do not interrupt smoke during the study.

          4. Intake of more than 25g of alcohol per day (equivalent to 750 mL of beer or 250 mL of
             wine, or 75 mL of white wine of 38 °, or 50 mL of white wine of ≥40 ° ). Subject who
             are positive for alcohol breath test or cannot stop drinking during the study.

          5. Women with pregnant, lactating or menstruating.

          6. History of previous hemoptysis, blood stool, skin mucosal bleeding points, etc., or
             bleeding tendency (patients with gingival, nasal, skin, mucosal bleeding, hemoptysis).

          7. History of active bleeding (peptic ulcer, hemorrhoids, active tuberculosis, subacute
             bacterial endocarditis, etc.).

          8. The examination show arteriovenous malformation, hemangioma and other vascular
             abnormalities.

          9. The examination show that there is hemorrhage in the fundus.

         10. The platelet count is less than 150×109/L.

         11. History of trauma (craniocerebral trauma, etc.) within 1 year.

         12. History of unexplained syncope or convulsions.

         13. History of autoimmune diseases, such as systemic lupus erythematosus.

         14. History of organic or mental illnesses or disabilities.

         15. According to the judgment by the researchers, subjects with low possibility of
             enrollment (such as weak body, etc.).

         16. Donation of blood in the last 3 months or participation in other clinical trials in
             the last 3 months.

         17. Previously recruited into other clinical studies of the product.

         18. Mental, psychological, or language disorders that prevent understanding or
             cooperation.

         19. Unwilling or unable to comply with the study schedule or procedure.

         20. Unfit to participate in the study for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ningru Zhang</last_name>
    <role>Study Director</role>
    <affiliation>Bengbu Medical College First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bengbu Medical College First Hospital</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

